Results 21 to 30 of about 35,256 (161)
Haematologica, 2012 Background Fc gamma receptor polymorphisms were linked to outcome in follicular lymphoma patients treated with single-agent rituximab, an anti-CD20 monoclonal antibody.
Daniel O. Persky +9 more
doaj +1 more source
Immunosuppression with Rituximab in Glomerular Diseases in Adults: Who, How and When?
Revista Portuguesa de Nefrologia e Hipertensão, 2023 Rituximab, a monoclonal antibody with the ability to bind itself to CD20, leads to a rapid depletion of B-cells (in around 24-72 hours), limiting antibody formation.
Raquel Pereira Sousa Pinto +8 more
doaj +1 more source
Immune responses to SARS‐CoV‐2 vaccination in multiple sclerosis: a systematic review/meta‐analysis
Annals of Clinical and Translational Neurology, 2022 Introduction Responses to SARS‐CoV‐2 vaccination in patients with MS (pwMS) varies by disease‐modifying therapies (DMTs). We perform a meta‐analysis and systematic review of immune response to SARS‐CoV‐2 vaccines in pwMS.
Grace Y. Gombolay +2 more
doaj +1 more source
Frontiers in Immunology, 2021 One mechanism by which monoclonal antibodies (mAb) help treat cancer or autoimmune disease is through triggering antibody-dependent cellular cytotoxicity (ADCC) via CD16 on Natural Killer (NK) cells.
Alexandros Karampatzakis +8 more
doaj +1 more source
Evolution of anti- CD20 monoclonal antibody therapeutics in oncology [PDF]
mAbs, 2010 Approval of an anti-CD20 chimeric monoclonal antibody, rituximab, has revolutionized cancer treatment and also validated CD20 targeting for providing benefit and improvement of overall response rate in B cell malignancies. Although many patients have benefited from the treatment of rituximab, there are still significant numbers of patients who are ...
Ezogelin, Oflazoglu, Laurent P, Audoly
openaire +2 more sources
A case of chronic myelomonocytic leukemia complicated with immune thrombocytopenia
Shanghai Jiaotong Daxue xuebao. Yixue banChronic myelomonocytic leukemia (CMML) complicated with immune thrombocytopenia (ITP) is rare. This article reports the clinical data of a patient with CMML complicated with ITP treated with a combination of venetoclax, ripertamab (an anti-CD20 ...
LIU Jiayu, HUANG Fang, HAO Siguo
doaj +1 more source
Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment
Scientific Reports, 2020 Lymphoma is the most common hematological cancer in dogs. Canine diffuse large B cell lymphoma shows a relatively good response to treatment with multi-agent cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy; however, the 2 ...
Takuya Mizuno +12 more
doaj +1 more source
Biomedicines, 2022 Disease- and treatment-mediated immunodeficiency might render SARS-CoV-2 vaccines less effective in patients with hematologic diseases. We performed a prospective non-interventional study to evaluate humoral response after one and two doses of mRNA-1273,
Zrinka Sertić +17 more
doaj +1 more source
Anti-CD20 monoclonal antibodies: historical and future perspectives
Haematologica, 2009 Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto-immune B-lymphocytes by rituximab has demonstrated substantial benefits for patients with a variety of B-cell lymphomas, as well as some with autoimmune disorders. There has been
Lim, Sean H. +5 more
openaire +4 more sources
GA101 (a Novel Anti-CD20 Monoclonal Antibody)-Induced Lichenoid Eruption [PDF]
Dermatology and Therapy, 2012 Obinutuzumab (GA101) is a novel anti-CD20 monoclonal antibody that has been shown to be effective for the treatment of non-Hodgkin's lymphoma, and is currently being evaluated in phase 3 clinical trials. The side-effect profile of the drug is not yet well established.The authors report a case of a 62-year-old patient who developed widespread lichenoid ...
Bakkour, Waseem, Coulson, Ian H.
openaire +2 more sources